13F Holdings
中文EN

HYPR Hyperfine, Inc.

Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1833769 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY80.0%
TTM net income YoY25.6%
TTM EPS YoY44.2%
Revenue 3-yr CAGR25.0%
Net income 3-yr CAGR—

Margins

Gross margin52.6%
Operating margin-167.6%
Net margin-156.4%
FCF margin-146.5%
EBITDA margin-162.0%

Returns

ROE-101.7%
ROA-60.0%
ROIC (approx.)-402.8%
Asset turnover0.38x

Leverage & solvency

Liabilities / assets45.1%
Debt / equity0.42x
Current ratio5.10x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.92x
Accruals ratio-4.5%
Payout ratio—
Capex / revenue1.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$13.56M$12.89M$11.03M$6.81M$1.50M
Cost of revenue$6.81M$7.00M$6.28M$5.91M$2.66M
Gross profit$6.75M$5.89M$4.76M$907,000-$1.17M
R&D expense$17.45M$22.50M$22.49M$28.16M$25.84M
SG&A expense$16.25M$17.49M$20.28M$32.41M$27.50M
Operating income-$37.09M-$43.22M-$48.12M-$73.87M-$64.87M
Pretax income-$35.57M-$40.72M-$44.24M-$73.16M-$64.85M
Income tax$0$0$0$0$0
Net income-$35.57M-$40.72M-$44.24M-$44.24M-$64.85M
EBITDA-$35.99M-$42.22M-$47.06M-$72.86M-$64.14M
EPS (basic)-0.43-0.56-0.62-1.04-17.57
EPS (diluted)-0.43-0.56-0.62-1.04-17.57
Weighted avg. shares (diluted)81.80M72.41M71.32M70.45M3.69M
Balance sheet
Cash & equivalents$35.09M$37.67M$75.80M$118.24M$191.16M
Receivables$5.25M$5.96M$3.19M$2.10M$553,000
Inventory$7.09M$5.83M$6.58M$4.62M$4.31M
Current assets$50.91M$53.71M$88.91M$128.66M$197.49M
PP&E, net$2.55M$3.12M$3.00M$3.25M$3.75M
Total assets$55.26M$58.90M$94.20M$134.05M$202.47M
Current liabilities$11.73M$8.73M$8.77M$8.80M$15.74M
Long-term debt$0————
Total debt$0————
Total liabilities$14.26M$9.86M$9.80M$10.33M$16.25M
Shareholders' equity$41.01M$49.04M$84.40M$123.72M$186.23M
Net debt-$35.09M————
Cash flow statement
Operating cash flow-$27.95M-$38.77M-$41.81M-$72.34M-$47.18M
Capital expenditure$1.19M$383,000$804,000$585,000$2.71M
Free cash flow-$29.13M-$39.15M-$42.61M-$72.92M-$49.89M
Investing cash flow-$1.19M-$383,000-$804,000-$585,000-$2.71M
Financing cash flow$27.50M$1.02M$174,000$7,000$176.77M
Depreciation & amortization$1.09M$1.01M$1.05M$1.01M$726,000
Stock-based compensation$2.80M$4.36M$4.74M$10.65M$6.90M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.